• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arena Reports Third Quarter Financial Results and Key Program Updates

    11/4/21 4:05:00 PM ET
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARNA alert in real time by email

    –  Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout

    –  First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis

    –  Strong liquidity position to support continued pipeline progress

    Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

    "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continue to look forward to the data readout in the first quarter of next year."

    Key Program & Corporate Updates

    Gastroenterology

    • In August the Phase 3 ELEVATE UC 12 trial for etrasimod in ulcerative colitis reached full enrollment; topline data for both ELEVATE UC 12 and ELEVATE UC 52 expected contemporaneously in Q1 2022
    • In August announced collaboration with Second Genome to identify microbiome biomarkers associated with clinical benefit in the CULTIVATE program for Crohn's disease
    • In August increased target enrollment in CULTIVATE study A from 50 participants to 70 participants; dose-ranging data anticipated to read out in early Q2 2022; enhanced data may allow transition to a registrational program and reduction of the overall program timeline

    Dermatology

    • In July we evaluated an updated OLE data set from the Phase 2 ADVISE trial for 2 mg etrasimod in atopic dermatitis that demonstrated meaningful effects at week 16 of the OLE period on validated Investigator Global Assessment (vIGA) at 47%, Eczema Area and Severity Index (EASI-75) at 72%, and Peak Pruritis Numeric Rating Scale (PP-NRS) at 61% with consistent safety profile out to one year
    • In July the Phase 2 trial for etrasimod in alopecia areata was amended to add a 3 mg cohort and expand patient population subtypes; topline data expected 2H 2022

    Cardiovascular

    • In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis
    • In July a Phase 2 trial for APD418 in acute heart failure was initiated

    Corporate Updates

    • In July we entered into a strategic collaboration and option agreement with Aristea for the development of RIST4721, an oral, selective CXCR2 antagonist being developed for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases
    • In July Dr. Doug Manion was appointed as Executive Vice President, Research & Development

    Financial Update

    Third Quarter 2021 Financial Results

    • Research and development (R&D) expenses for the third quarter totaled $94.2 million compared to $79.8 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as well as an increase in personnel expenses to support our clinical programs. The R&D non-cash, share-based compensation was $8.1 million in the third quarter as compared to $6.6 million in the same period in 2020
    • Selling, general and administrative (SG&A) expenses for the third quarter totaled $30.3 million, compared to $19.0 million in the third quarter of 2020. This increase was primarily driven by an increase in personnel expenses and other professional fees. The SG&A non-cash, share-based compensation was $9.2 million in the third quarter as compared to $5.8 million in the same period in 2020
    • Net loss for the third quarter was $196.3 million compared to net loss of $97.4 million for the same period in 2020. This includes $70 million of Acquired In-Process R&D expense associated with our recently announced collaboration with Aristea Therapeutics
    • Basic and diluted net loss per share for the third quarter was $3.21 compared to basic and diluted net loss per share of $1.69 for the same period in 2020
    • Cash, cash equivalents and marketable securities were $0.8 billion at September 30, 2021 as compared to $1.1 billion at December 31, 2020. In addition to normal operating cash burn for the quarter, we made a $70 million payment in connection with our recently announced collaboration with Aristea Therapeutics

    Conference Call & Webcast Information

    Arena will host a conference call and live webcast to discuss the financial results and corporate update via a question and answer session with the investment community today, Thursday, November 4, 2021, at 4:30 PM ET.

    Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations. Shortly after the event, a recording will be archived under the investor relations section of Arena's website for 30 days.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done.

    ARENA - Care More. Act Differently.

    Etrasimod, temanogrel, and APD418 are investigational compounds that are not approved for any use in any country.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as "on course," "on track," "look forward to," "expected," and "anticipated" and include, without limitation, statements about the following: Arena's clinical programs, including expectations regarding study progress, the timing of data readouts for ongoing trials, and other statements under "Key Program & Corporate Updates" above. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: clinical trials and other studies may not proceed at the time or in the manner expected or at all; topline data may not accurately reflect the complete results of a particular study or trial; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; the timing and outcome of research, development and regulatory review is uncertain, and Arena's drug candidates may not advance in development or be approved for marketing; enrolling patients in Arena's ongoing and intended clinical trials is competitive and challenging; the duration and severity of the coronavirus disease (COVID-19) pandemic, including but not limited to the impact on Arena's clinical operations, the operations of Arena's suppliers, partners, collaborators, licensees, and capital markets, which in each case remains uncertain; risks related to developing and commercializing drugs; Arena will need additional funds to advance all of its programs; the impact of competition; risks related to unexpected or unfavorable new data; the risk that regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; satisfactory resolution of litigation or other disagreements with others; and risks related to the enforcement of Arena's and third parties' intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, which was filed with the SEC on August 5, 2021. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Arena Pharmaceuticals, Inc.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (Unaudited)

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2021

     

    2020

     

    2021

     

    2020

    Revenues:

     

     

     

     

     

     

     

    Collaboration and other revenue

    $

    —

     

     

     

    $

    20

     

     

     

    $

    —

     

     

     

    $

    20

     

     

    Royalty revenue

    —

     

     

     

    —

     

     

     

    —

     

     

     

    262

     

     

    Total revenues

    —

     

     

     

    20

     

     

     

    —

     

     

     

    282

     

     

    Operating Costs and Expenses:

     

     

     

     

     

     

     

    Research and development

    94,180

     

     

     

    79,820

     

     

     

    309,168

     

     

     

    223,299

     

     

    Acquired in-process research and development

    70,000

     

     

     

    —

     

     

     

    70,000

     

     

     

    —

     

     

    Selling, general and administrative

    30,305

     

     

     

    19,002

     

     

     

    91,701

     

     

     

    68,321

     

     

    Total operating costs and expenses

    194,485

     

     

     

    98,822

     

     

     

    470,869

     

     

     

    291,620

     

     

    Loss from operations

    (194,485

    )

     

     

    (98,802

    )

     

     

    (470,869

    )

     

     

    (291,338

    )

     

    Interest and Other Income (Expense):

     

     

     

     

     

     

     

    Interest income

    205

     

     

     

    1,825

     

     

     

    1,223

     

     

     

    9,836

     

     

    Interest expense

    (1,031

    )

     

     

    (1,120

    )

     

     

    (3,155

    )

     

     

    (3,427

    )

     

    Other (expense) income, net

    (1,001

    )

     

     

    659

     

     

     

    (1,892

    )

     

     

    2,356

     

     

    Gain from Longboard equity method investment

    —

     

     

     

    —

     

     

     

    13,869

     

     

     

    —

     

     

    Total interest and other income (expense), net

    (1,827

    )

     

     

    1,364

     

     

     

    10,045

     

     

     

    8,765

     

     

    Net loss

    $

    (196,312

    )

     

     

    $

    (97,438

    )

     

     

    $

    (460,824

    )

     

     

    $

    (282,573

    )

     

     

     

     

     

     

     

     

     

    Net loss per share, basic and diluted:

    $

    (3.21

    )

     

     

    $

    (1.69

    )

     

     

    $

    (7.61

    )

     

     

    $

    (5.27

    )

     

     

     

     

     

     

     

     

     

    Shares used in calculating net loss per share, basic and diluted:

    61,140

     

     

     

    57,779

     

     

     

    60,574

     

     

     

    53,608

     

     

     

    Arena Pharmaceuticals, Inc.

    Condensed Consolidated Balance Sheet Data

    (In thousands, except share data)

    (Unaudited)

     

     

    September 30,

    2021

     

    December 31,

    2020

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    386,653

     

     

     

    $

    219,544

     

     

    Short-term investments, available-for-sale

    385,014

     

     

     

    884,497

     

     

    Prepaid expenses and other current assets

    19,253

     

     

     

    35,266

     

     

    Total current assets

    790,920

     

     

     

    1,139,307

     

     

    Investments, available-for-sale

    52,953

     

     

     

    —

     

     

    Land, property and equipment, net

    19,558

     

     

     

    22,090

     

     

    Other non-current assets

    37,596

     

     

     

    29,323

     

     

    Total assets

    $

    901,027

     

     

     

    $

    1,190,720

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and other accrued liabilities

    $

    30,037

     

     

     

    $

    35,351

     

     

    Accrued clinical and preclinical study fees

    18,434

     

     

     

    18,325

     

     

    Current portion of lease financing obligations

    4,884

     

     

     

    4,401

     

     

    Total current liabilities

    53,355

     

     

     

    58,077

     

     

    Other long-term liabilities

    9,466

     

     

     

    10,963

     

     

    Lease financing obligations, less current portion

    37,485

     

     

     

    41,211

     

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock, $0.0001 par value, 7,500,000 shares authorized, no shares issued and outstanding at September 30, 2021 and December 31, 2020

    —

     

     

     

    —

     

     

    Common stock, $0.0001 par value, 147,000,000 shares authorized at September 30, 2021 and December 31, 2020; 61,280,176 and 58,611,210 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

    6

     

     

     

    6

     

     

    Additional paid-in capital

    2,769,148

     

     

     

    2,587,494

     

     

    Accumulated other comprehensive income

    122

     

     

     

    700

     

     

    Accumulated deficit

    (1,968,555

    )

     

     

    (1,507,731

    )

     

    Total stockholders' equity

    800,721

     

     

     

    1,080,469

     

     

    Total liabilities and stockholders' equity

    $

    901,027

     

     

     

    $

    1,190,720

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006169/en/

    Get the next $ARNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARNA

    DatePrice TargetRatingAnalyst
    2/9/2022$120.00 → $100.00Buy → Neutral
    HC Wainwright & Co.
    12/21/2021$93.00 → $100.00Overweight → Neutral
    Cantor Fitzgerald
    12/14/2021Market Outperform → Market Perform
    JMP Securities
    12/14/2021$112.00 → $100.00Outperform → Market Perform
    SVB Leerink
    12/14/2021$76.00 → $100.00Outperform → Sector Perform
    RBC Capital
    12/14/2021$98.00 → $100.00Outperform → Neutral
    Credit Suisse
    12/14/2021$100.00Buy → Hold
    Jefferies
    12/13/2021Buy → Hold
    Needham
    More analyst ratings

    $ARNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

      2/17/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Arena Pharmaceuticals Inc.

      15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/21/22 6:03:29 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:11 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:08 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt

      7/19/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv

      6/14/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:43 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:23 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:23:59 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arena Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously

      2/9/22 6:14:57 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

      12/21/21 5:12:52 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform

      12/14/21 7:04:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/11/22 10:07:09 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/9/22 3:24:50 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/4/22 9:26:03 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Financials

    Live finance-specific insights

    See more
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

      2/9/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer to Acquire Arena Pharmaceuticals

      Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

      12/13/21 6:45:00 AM ET
      $ARNA
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care